Targeting the Complexity of In Vitro Skin Models: A Review of Cutting-Edge Developments DOI Creative Commons
Cristina Quílez, Luís B. Bebiano, Eleri Jones

et al.

Journal of Investigative Dermatology, Journal Year: 2024, Volume and Issue: 144(12), P. 2650 - 2670

Published: Aug. 10, 2024

Skin in vitro models offer much promise for research, testing drugs, cosmetics, and medical devices, reducing animal extensive clinical trials. There are several approaches to mimicking human skin behavior, ranging from simple cell monolayer complex organotypic bioengineered 3-dimensional models. Some have been approved preclinical studies pharmaceuticals, chemicals. However, development of physiologically reliable remains its infancy. This review reports on advances study homeostasis, aging, disease. The generation that accurately reproduce all layers (epidermis, dermis, subcutis), including appendages such as sweat glands (SGs), hair follicles, or arrector pili muscle, represents a significant hurdle the field tissue engineering. we still far full cellular structural complexity living (Antoni et al., 2015Antoni D. Burckel H. Josset E. Noel G. Three-dimensional culture: breakthrough vivo.Int J Mol Sci. 2015; 16: 5517-5527Crossref PubMed Scopus (699) Google Scholar; Sanabria-de la Torre 2020Sanabria-de R. Fernández-González A. Quiñones-Vico M.I. Montero-Vilchez T. Arias-Santiago S. Bioengineered intended model Pharmacosmetics, disease environmental impact analysis.Biomedicines. 2020; 8: 464Crossref (17) Sutterby 2022Sutterby Thurgood P. Baratchi Khoshmanesh K. Pirogova Evaluation studying effects external stressors stimuli developing treatment modalities.View. 2022; 320210012Crossref (18) Scholar). demand innovative effective (3D) engineered equivalents has increased not only improving purposes grafts but also essential (patho)physiological investigations, unravel underlying mechanisms disorders well assessing effectiveness potential toxicity active substances cosmetic pharmaceutical research (Olejnik 2022Olejnik Semba J.A. Kulpa Dańczak-Pazdrowska Rybka J.D. Gornowicz-Porowska J. 3D bioprinting related research: recent achievements application perspectives.ACS Synth Biol. 11: 26-38Crossref (40) Salameh 2021Salameh Tissot N. Cache Lima Suzuki I. Marinho P.A. al.A perfusable vascularized full-thickness topical systemic applications.Biofabrication. 2021; 13035042Crossref (30) Current aim replicate critical characteristics, barrier function, elasticity, immune response, blood flow, technical biological issues limit true functional (Klicks 2017Klicks von Molitor Ertongur-Fauth Rudolf Hafner M. In three-dimensional their applications.J Cell Biotechnol. 2017; 3: 21-39Crossref evolution substitutes paralleled technological resulted with varying degrees complexity. Although is linear, main drive innovation lies physiologic relevance (Figure 1). simplest approach 2-dimensional (2D) culture primary keratinocytes fibroblasts. do cell–cell cell–matrix communication organization skin, they very useful drug screening; cytotoxicity assays; molecular diseases cancer (Duval 2017Duval Grover Han L.H. Mou Y. Pegoraro A.F. Fredberg al.Modeling physiological events 2D vs. culture.Physiology (Bethesda). 32: 266-277Crossref (1158) Hofmann 2023Hofmann Fink Pignet A.L. Schwarz Schellnegger Nischwitz S.P. al.Human wound healing disorders.Biomedicines. 2023; 1056Crossref Moon 2021Moon Kim D.H. Shin J.U. response skin.Yonsei Med 62: 969-980Crossref (0) Stanton 2022Stanton D.N. Ganguli-Indra Indra A.K. Karande efficacy disease: last 10 years.Pharmaceutics. 14: 319Crossref (5) Incorporation extracellular matrix (ECM) components into provided cells important cues native environment, promoting more representative growth, proliferation, function resembling some conditions vivo Langhans, 2018Langhans S.A. discovery repositioning.Front Pharmacol. 2018; 9: 6Crossref (1000) Sarkiri 2019Sarkiri Fox S.C. Fratila-Apachitei L.E. Zadpoor A.A. modeling.Int 2019; 20: 1407Crossref (24) Valdoz 2021Valdoz J.C. Johnson B.C. Jacobs D.J. Franks N.A. Dodson E.L. Sanders C. al.The ECM: scaffold, question.Int 2212690Crossref (60) systems includes organoids 1), simplified system which grow 3D-well chemically defined microenvironment—composed ECM media—to form self-organized clusters differentiate distinct types mimic structure organ (Corrò 2020Corrò Novellasdemunt L. Li V.S.W. A brief history organoids.Am Physiol Physiol. 319: C151-C165Crossref Hofer Lutolf, 2021Hofer Lutolf M.P. Engineering organoids.Nat Rev Mater. 6: 402-420Crossref (524) 2020bKim Koo B.K. Knoblich Human organoids: biology medicine.Nat 21: 571-584Crossref Whereas recapitulate different internal organs gut (Taelman 2022Taelman Diaz Guiu intestinal challenge.Front Dev 10854740Crossref (31) Scholar), lung (Matkovic Leko 2023Matkovic Schneider R.T. Thimraj T.A. Schrode Beitler Liu H.Y. distal organoid interstitial disease, viral infection development.Nat Protoc. 18: 2283-2312Crossref brain (Eichmüller Knoblich, 2022Eichmüller O.L. cerebral - new tool neurology research.Nat Neurol. 661-680Crossref (21) bladder (Minoli 2023Minoli Cantore Hanhart Kiener Fedrizzi La Manna F. al.Bladder stages therapy response.Nat Commun. 2214Crossref tumors (Xu 2022Xu Jiao Wu Tumor applications modeling potentials precision medicine.J Hematol Oncol. 15: 58Crossref (69) traditional consist 2 dermo–epidermal formed by fibroblasts embedded an gel cultured top gel, generated insert's porous membrane allow epidermal keratinization (Gangatirkar 2007Gangatirkar Paquet-Fifield Rossi Kaur Establishment cultures using neonatal cells.Nat 2007; 2: 178-186Crossref (124) These (HSEs) well-established available market (Hayden 2003Hayden P.J. Ayehunie Jackson G.R. Kupfer-Lamore Last T.J. al.In equivalent testing.in: Alternative toxicological methods. CRC Press, Boca Raton2003: 229-248Google Suhail 2019Suhail Sardashti Jaiswal Rudraiah Misra Kumbar S.G. Engineered product evaluation therapeutic applications.Biotechnol 14e1900022Crossref (46) Presently, there range commercially HSEs offering source screening, tests, sensitivity tests (Table Several patients, animal-based, ex assays used identify potentially irritant chemicals compatible high-throughput screening required industry. This, along legislative move toward nonanimal (European Regulation 1223/2009 United States Federal Food, Drug, Cosmetic Act, 2022), prompted commercial regulatory toxicology, validated epithelial-only methods corrosion irritation adopted Organisation Economic Co-operation Development (Test Guidelines 431 439, respectively) (Kandárová 2006Kandárová Liebsch Schmidt Genschow Traue Spielmann al.Assessment SkinEthic reconstructed common protocol evaluated ECVAM validation study.Altern Lab Anim. 2006; 34: 393-406Crossref (52) 2007Spielmann Hoffmann Botham Fentem J.H. Eskes international acute irritation: report validity Episkin EpiDerm Integrity Function Test.Altern 35: 559-601Crossref (184) based metabolic activity, provide indirect measure viability, 50% threshold set acceptable chemical safety levels. More sophisticated (KeratinoSens [Andreas 2011Andreas Caroline B. Leslie Frank Kimberly Allison intra- inter-laboratory reproducibility predictivity KeratinoSens assay predict sensitizers vitro: results ring-study five laboratories.Toxicol Vitro. 2011; 25: 733-744Crossref (98) Emter 2010Emter Ellis Natsch Performance novel keratinocyte-based reporter line screen vitro.Toxicol Appl 2010; 245: 281-290Crossref (269) Scholar] LuSens [Ramirez 2014Ramirez Mehling Kolle S.N. Wruck C.J. Teubner W. Eltze al.LuSens: keratinocyte ARE gene use integrated strategies sensitization hazard identification.Toxicol 2014; 28: 1482-1497Crossref (104) Scholar]) utilize luciferase basis induced activation transcription factor, nuclear factor erythroid 2. these architecture permeability yet be translated systems. number altered expression profiles known irritants, SENS-IS being currently most developed (Cottrez 2015Cottrez Boitel Auriault Aeby Groux Genes specifically modulated sensitized skins detection model. assay.Toxicol 29: 787-802Crossref (80) Harding 2021Harding Murdoch Danby Hasan M.Z. Nakanishi Furuno al.Determination signature tissue-engineered equivalents.JID Innov. 1100011Abstract Full Text PDF (3) 2019Hasan Kitamura Kawai Ohira Mori Shoju al.Transcriptional profiling lactic acid treated epidermis reveals pathways stinging itch.Toxicol 57: 164-173Crossref (13) Saito 2017Saito Takenouchi O. Nukada Miyazawa Sakaguchi An termed EpiSensA broad sets lipophilic pre/pro-haptens.Toxicol 40: 11-25Crossref (33) recently, 2023Harding Colley H.E. Vazquez I.B. al.c-Src marker chemical-induced equivalents.Exp Dermatol. 220-225Crossref (1) Scholar analyzed immediate up-stream signaling cascades upon irritants specific kinases could tested rapid formats. Despite evident progress HSEs, constraint lack neural compartment, isolating stimulus rather than providing orchestrated feedback whole (Basso 2019Basso Serhan Tauber Gaudenzio Peripheral neurons: master regulators mucosal response.Eur Immunol. 49: 1984-1997Crossref Cohen 2020Cohen Kaplan Neuronal regulation cutaneous immunity.J 204: 264-270Crossref (27) Trier 2019Trier A.M. Mack M.R. B.S. neuroimmune axis sensation, inflammation, 202: 2829-2835Crossref (36) Scholar).Table 1Commercially Available Full-Thickness HSECompanySystemRegional AvailabilityReferenceEpiSkin, Lyon, FranceT-SkinGlobalBataillon 2019Bataillon Lelièvre Chapuis Thillou Autourde J.B. Durand al.Characterization thickness model, T-SkinTM, investigations anti-aging compounds.Int 2240Crossref Luu-The 2009Luu-The V. Duche Ferraris Meunier J.R. Leclaire Labrie Expression phases 1 metabolizing enzymes Episkin.J Steroid Biochem 2009; 116: (75) ScholarMatTek, Ashland, MAEpiDermFTGlobalMallampati 2010Mallampati Patlolla R.R. Agarwal Babu R.J. Hayden Klausner al.Evaluation thickness-300 (EFT-300) aliphatic hydrocarbons.Toxicol 24: 669-676Crossref ScholarPhenion, Henkel AG KGaA, Düsseldorf, GermanyPhenion FTEurope (and wider1More specifically, supply places reachable courier service within 72 hours.)Pinto 2022Pinto Trink Giuliani Rinaldi Protective sunscreen (50+) octatrienoic 0.1% actinic keratosis UV damages.J Investig Med. 70: 92-98Crossref ScholarSterlab, Vallauris, FranceFull-thickness skin——Abbreviation: HSE, equivalent.1 hours. Open table tab Abbreviation: equivalent. academia, persisting efforts made sophisticate increase experimental throughput complexity, while methodological aspects faithfully diseases. Here, large collaborative networks formed, similar European Network Modeling (NETSKINMODELS) EU COST Action (CA21108, 2022-2026) over 330 participants 40 countries both academia industry united. With this review, members NETSKINMODELS now stage current developments knowledge technology gaps guidelines resources later fuel implementation academic industrial research. earlier-mentioned properly resemble physiopathology presence circulatory flow imitating vessels distributes nutrients other molecules. addition, natural growth occurs simultaneously body exposed multiple stresses conditions. Therefore, diverse dynamic microfluidic devices stimulate facilitate key tissues vitro, example, bioreactors chip (SoC) 2a). projected induce vivo–like biophysiological at bench scale stimulate, mature, monitor, prolong healthy duration. stretch-based bioreactors—either unidirectional, bidirectional, radial force—to mature basement (Tokuyama 2015Tokuyama Nagai Takahashi Kimata Naruse Mechanical stretch increases develops membrane.PLoS One. 10e0141989Crossref (44) stratum corneum (Jung 2016Jung M.H. Jung S.M. H.S. Co-stimulation HaCaT mechanical stress air-exposure device.Sci Rep. 2016; 633889Crossref (23) stiffer dermis (Wahlsten 2021Wahlsten Rütsche Nanni Giampietro Biedermann Reichmann al.Mechanical stimulation induces fibroblast proliferation accelerates early maturation substitutes.Biomaterials. 273120779Crossref wrinkled (Lim 2018Lim Song H.J. Choi K.C. Park al.Development skin-on-a-chip (WSOC) cyclic uniaxial stretching.J Ind Eng Chem. 68: 238-245Crossref (37) Because maintenance process involving biophysiological, chemical, stimuli, tend simplify focus introduction few design development. Nowadays, can find bioreactor techniques cultivation models: perfusion 2b–h). Perfusion fresh media same time removal waste metabolites. enable shear cells, produced endothelium, responsible various protein synthesis division. channel placed just below (Lee 2017Lee Jin Y.K. Sung G.Y. Chung Construction multicellular model.Biomed Microdevices. 19: 22Crossref (97) Rimal 2021Rimal Marquardt Nevolianis Djeljadini Marquez A.B. Huth al.Dynamic enables long-term 3-D models.Appl Mater Today. 25101213Google 2018Song Lim Chun Lee skin-equivalent pump-less chip.J 60: 355-359Crossref (38) Scholar) around (Sriram 2018Sriram Alberti Dancik Feng Z. al.Full-thickness skin-on-chip enhanced morphogenesis function.Mater 326-340Crossref (185) passively gravity-based platform peristaltic pump (Rimal Sriram across dermal compartment vascular network (Mori 2017Mori Morimoto Takeuchi channels chip.Biomaterials. 48-56Crossref Owing variable demands needed desired dedicated HSEs. Nevertheless, ample evidence benefits cultures, soon expect shift cultures. will lead cheaper, For this, upcoming simplification, ease use, less manual input modular integration sensors, apparatus single platform. trends require realistic environment analysis. succeed first, macroscale limited scalability. regard, SoCs miniaturized microflows, forces, gradients obtain accurate treatments drugs (Abaci 2016Abaci Guo Coffman Gillette W.-H. Sia S.K. constructs spatially controlled vasculature iPSC-derived endothelial cells.Adv Healthc 5: 1800-1807Crossref 2018Mori Perfusable stretchable skin-equivalent.Biofabrication. 11011001Crossref (51) Scholar, SoC platforms divided groups, depending inside 2). First, microfluidics biopsies transferred SoCs. original definition organ-on-a-chip given Ingber (Bhatia Ingber, 2014Bhatia D.E. Microfluidic organs-on-chips.Nat 760-772Crossref (2406) shown good when transdermal transport bacterial infections 2015Abaci Gledhill Christiano Shuler M.L. Pumpless equivalents.Lab Chip. 882-888Crossref 2019aKim J.J. Ellett Thomas C.N. Jalali Anderson Irimia microscale, full-thickness, simulating neutrophil responses antibiotic treatments.Lab 3094-3103Crossref commonly multiorgan-on-a-chip (Maschmeyer 2015Maschmeyer Lorenz Schimek Hasenberg Ramme A.P. Hübner four-organ-chip interconnected co-culture intestine, liver, kidney 2688-2699Crossref Wagner 2013Wagner Materne E.M. Brincker Süssbier U. Frädrich Busek multi-organ-chip substance proven liver co-culture.Lab 2013; 13: 3538-3547Crossref second group refers those directly device. monolayers, either (Ramadan Ting, 2016Ramadan Q. Ting F.C. micro-physiological immune-competent skin.Lab 1899-1908Crossref monolayers (Wufuer 2016Wufuer Hur Jeon B.J. T.H. al.Skin-on-a-chip edema drug-based treatment.Sci 637471Crossref (234) groups gone step further, generating structures device, single-differentiated (Zhang 2021Zhang Chen Zhang Wang X. Ouyang Zhu al.Construction high fidelity epidermis-on-a-chip scalable evaluation.Lab 3804-3818Crossref 2Summary Dynamic Models Found LiteratureType PlatformDermal MatrixCellsApplicationReferenceMicrofluidic platformNoneNormal keratinocytesNHKs cultureO'Neill 2008O'Neill A.T. Monteiro-Riviere Walker G.M. Characterization culture.Cytotechnology. 2008; 56: 197-207Crossref ScholarVascularized HSECollagenNormal + HUVECsPercutaneous absorption, permeabilityMori HSECollagenPrimary

Language: Английский

Recent advances in targeted strategies for triple-negative breast cancer DOI Creative Commons
Shuangli Zhu, Yuze Wu, Bin Song

et al.

Journal of Hematology & Oncology, Journal Year: 2023, Volume and Issue: 16(1)

Published: Aug. 28, 2023

Triple-negative breast cancer (TNBC), a highly aggressive subtype of cancer, negatively expresses estrogen receptor, progesterone and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is main form treatment for patients with TNBC, effectiveness TNBC still limited. The search more effective therapies urgent. Multiple targeted therapeutic strategies have emerged according to specific molecules signaling pathways expressed in TNBC. These include PI3K/AKT/mTOR inhibitors, Notch poly ADP-ribose polymerase antibody-drug conjugates. Moreover, immune checkpoint example, pembrolizumab, atezolizumab, durvalumab, are widely explored clinic. We summarize recent advances therapy immunotherapy aim serving as reference development individualized future.

Language: Английский

Citations

112

Drug repurposing for cancer therapy DOI Creative Commons
Ying Xia, Ming Sun, Hai Huang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: April 18, 2024

Abstract Cancer, a complex and multifactorial disease, presents significant challenge to global health. Despite advances in surgical, radiotherapeutic immunological approaches, which have improved cancer treatment outcomes, drug therapy continues serve as key therapeutic strategy. However, the clinical efficacy of is often constrained by resistance severe toxic side effects, thus there remains critical need develop novel therapeutics. One promising strategy that has received widespread attention recent years repurposing: identification new applications for existing, clinically approved drugs. Drug repurposing possesses several inherent advantages context since repurposed drugs are typically cost-effective, proven be safe, can significantly expedite development process due their already established safety profiles. In light this, present review offers comprehensive overview various methods employed repurposing, specifically focusing on treat cancer. We describe antitumor properties candidate drugs, discuss detail how they target both hallmarks tumor cells surrounding microenvironment. addition, we examine innovative integrating with nanotechnology enhance topical delivery. also emphasize role play when used part combination regimen. To conclude, outline challenges associated consider future prospects these transitioning into application.

Language: Английский

Citations

104

AI-enabled organoids: Construction, analysis, and application DOI Creative Commons
Long Bai,

Yan Wu,

Guangfeng Li

et al.

Bioactive Materials, Journal Year: 2023, Volume and Issue: 31, P. 525 - 548

Published: Sept. 16, 2023

Organoids, miniature and simplified

Language: Английский

Citations

68

Spatiotemporal, optogenetic control of gene expression in organoids DOI Creative Commons
Ivano Legnini, Lisa Emmenegger,

Alessandra Zappulo

et al.

Nature Methods, Journal Year: 2023, Volume and Issue: 20(10), P. 1544 - 1552

Published: Sept. 21, 2023

Organoids derived from stem cells have become an increasingly important tool for studying human development and modeling disease. However, methods are still needed to control study spatiotemporal patterns of gene expression in organoids. Here we combined optogenetics perturbation technologies activate or knock-down RNA target genes programmable patterns. To illustrate the usefulness our approach, locally activated Sonic Hedgehog (SHH) signaling organoid model neurodevelopment. Spatial single-cell transcriptomic analyses showed that this local induction was sufficient generate stereotypically patterned organoids revealed new insights into SHH's contribution regulation With study, propose optogenetic perturbations combination with spatial transcriptomics as a powerful technology reprogram cell fates tissue patterning

Language: Английский

Citations

47

Landscape of human organoids: Ideal model in clinics and research DOI Creative Commons
Xinxin Han, Chunhui Cai, Wei Deng

et al.

The Innovation, Journal Year: 2024, Volume and Issue: 5(3), P. 100620 - 100620

Published: April 1, 2024

In the last decade, organoid research has entered a golden era, signifying pivotal shift in biomedical landscape. The year 2023 marked milestone with publication of thousands papers this arena, reflecting exponential growth. However, amid burgeoning expansion, comprehensive and accurate overview field been conspicuously absent. Our review is intended to bridge gap, providing panoramic view rapidly evolving We meticulously analyze from eight distinctive vantage points, harnessing our rich experience academic research, industrial application, clinical practice. present deep exploration advances technology, underpinned by long-standing involvement arena. narrative traverses historical genesis organoids their transformative impact across various sectors, including oncology, toxicology, drug development. delve into synergy between avant-garde technologies such as synthetic biology single-cell omics discuss role tailoring personalized medicine, enhancing high-throughput screening, constructing physiologically pertinent disease models. analysis reflective discourse provide dive existing landscape emerging trends technology. spotlight technological innovations, methodological evolution, broadening spectrum applications, emphasizing revolutionary influence discovery, other fields. Looking ahead, we cautiously anticipate future developments especially its potential implications for patient care, new avenues research. trust that will be an asset researchers, clinicians, patients keen interest medical strategies. offer broad prospective capabilities encompassing wide range current applications. summary, attempt field. reflections, summaries, projections might useful researchers hope contribute shaping trajectory dynamic advancing

Language: Английский

Citations

30

Construction of tumor organoids and their application to cancer research and therapy DOI Creative Commons

Jiajing Lv,

Xuan Du, Miaomiao Wang

et al.

Theranostics, Journal Year: 2024, Volume and Issue: 14(3), P. 1101 - 1125

Published: Jan. 1, 2024

Cancer remains a severe public health burden worldwide.One of the challenges hampering effective cancer therapy is that existing models hardly recapitulate tumor microenvironment human patients.Over past decade, organoids have emerged as an in vitro 3D model to mimic pathophysiological characteristics parental tumors.Various techniques been developed construct organoids, such matrix-based methods, hanging drop, spinner or rotating flask, nonadhesive surface, organ-on-a-chip, bioprinting, and genetic engineering.This review elaborated on cell components fabrication methods for establishing organoid models.Furthermore, we discussed application modeling, basic research, anticancer therapy.Finally, current limitations future directions employing more extensive applications.

Language: Английский

Citations

21

Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine DOI Creative Commons
Shanqiang Qu, Rongyang Xu,

Guozhong Yi

et al.

Molecular Biomedicine, Journal Year: 2024, Volume and Issue: 5(1)

Published: Feb. 12, 2024

Abstract Cancer is associated with a high degree of heterogeneity, encompassing both inter- and intra-tumor along considerable variability in clinical response to common treatments across patients. Conventional models for tumor research, such as vitro cell cultures vivo animal models, demonstrate significant limitations that fall short satisfying the research requisites. Patient-derived organoids, which recapitulate structures, specific functions, molecular characteristics, genomics alterations expression profiles primary tumors. They have been efficaciously implemented illness portrayal, mechanism exploration, high-throughput drug screening assessment, discovery innovative therapeutic targets potential compounds, customized treatment regimen cancer In contrast conventional organoids offer an intuitive, dependable, efficient model by conserving phenotypic, genetic diversity, mutational attributes originating tumor. Nevertheless, organoid technology also confronts bottlenecks challenges, how comprehensively reflect microenvironment, angiogenesis, reduce costs, establish standardized construction processes while retaining reliability. This review extensively examines use techniques fundamental precision medicine. It emphasizes importance patient-derived biobanks development, screening, safety evaluation, personalized Additionally, it evaluates application experimental better understand mechanisms The intent this explicate significance present new avenues future research.

Language: Английский

Citations

17

Mechanisms and Strategies of Immunosenescence Effects on Non-Small Cell Lung Cancer (NSCLC) Treatment: A Comprehensive Analysis and Future Directions DOI
Huatao Zhou,

Zilong Zheng,

Chengming Fan

et al.

Seminars in Cancer Biology, Journal Year: 2025, Volume and Issue: 109, P. 44 - 66

Published: Jan. 9, 2025

Language: Английский

Citations

2

Optimized strategies of ROS-based nanodynamic therapies for tumor theranostics DOI

Yifan Di,

Ruizhu Deng,

Zhu Liu

et al.

Biomaterials, Journal Year: 2023, Volume and Issue: 303, P. 122391 - 122391

Published: Nov. 15, 2023

Language: Английский

Citations

37

Flourishing tumor organoids: History, emerging technology, and application DOI Creative Commons
Qian Yang, Mengmeng Li, Xinming Yang

et al.

Bioengineering & Translational Medicine, Journal Year: 2023, Volume and Issue: 8(5)

Published: June 7, 2023

Malignant tumors are one of the leading causes death which impose an increasingly heavy burden on all countries. Therefore, establishment research models that closely resemble original tumor characteristics is crucial to further understanding mechanisms malignant development, developing safer and more effective drugs, formulating personalized treatment plans. Recently, organoids have been widely used in owing their advantages including preserving structure, heterogeneity, cellular functions tumor, together with ease manipulation. This review describes history synergistic combination three-dimensional (3D) culture approaches for emerging technologies, tissue-engineered cell scaffolds, microfluidic devices, 3D bioprinting, rotating wall vessels, clustered regularly interspaced short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9). Additionally, progress applications basic clinical organoid summarized. includes studies mechanism drug development screening, precision medicine, immunotherapy, simulation microenvironment. Finally, existing shortcomings possible future directions discussed.

Language: Английский

Citations

28